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Abstract—Drug-eluting stents are now routinely used in the
treatment of acute coronary syndromes caused by coronary
artery disease.Whilst the sustained release of anti-proliferative
drugs from these devices has greatly reduced the need for
repeat revascularisation procedures, this approach is not
suitable for all patients and appears to delay regrowth of the
endothelium, necessitating the use of prolonged dual anti-
platelet therapy. Although the development of more advanced
stent platforms and drug coatings has produced modest
improvements in performance, these devices have not fully
addressed the limitations experienced with their ﬁrst-genera-
tion counterparts. In the present study, we developed a novel
stent coating that provides controlled sirolimus release from a
bioactive polymer (accelerateTM AT) that has previously been
shown to support endothelial cell growth in vitro. A bespoke
electrospray deposition process provided control over the
coating thickness, surface roughness, drug load, and release
kinetics. The resultant optimised coating combines rapid
release of an anti-proliferative agent from a bioactive polymer
coating that promotes re-endothelialisation, thereby offering
potential protection against in-stent restenosis and thrombo-
sis. This novel, dual-action coating therefore has signiﬁcant
therapeutic potential, with the enhanced control of drug load
and release kinetics offered by electrospray deposition also
opening up opportunities for more personalised treatment
approaches. Further development and evaluation of these
technologies in vitro and in vivo is therefore warranted.
Keywords—In-stent restenosis, Drug-eluting stent, Electro-
hydrodynamic spraying, Drug release, Stent-thrombosis.
INTRODUCTION
Coronary artery disease (CAD) is caused by hard-
ening and narrowing of the coronary arteries by
atherosclerotic plaques, which results in reduced arte-
rial blood ﬂow and perfusion of the myocardium,
leading to angina and localised ischaemia, which may
eventually result in infarction.25 The most widely used
treatment for CAD is now percutaneous coronary
intervention (PCI), which involves permanent deploy-
ment of a stent into the target vessel, leading to
immediate restoration of blood ﬂow and symptomatic
relief. Coronary stents are most commonly composed
of a metal alloy and provide the radial strength
required to maintain vessel patency. However, stenting
induces the formation of neointimal tissue, charac-
terised by inﬂammation and uncontrolled proliferation
of smooth muscle cells, eventually causing thickening
of the artery wall and late lumen loss.14 Drug-eluting
stents (DES) target this hyperplastic response, termed
in-stent restenosis (ISR), through the release of anti-
proliferative drugs.15 This approach has proven to be
very successful, with the incidence of ISR reduced from
around 30–40% with bare metal stents (BMS) to less
than 5% with DES.5 However, current DES are not as
effective in high-risk groups, including diabetic
patients and those with multi-vessel disease or complex
atherosclerotic lesions.5 The drugs used on DES also
inhibit endothelial cell proliferation, which may be an
important factor in the delayed recovery of the
endothelium that has been observed with DES.17 This
delayed recovery exposes the sub-endothelial space and
the stent surface to blood ﬂow and leaves the vessel
vulnerable to late and very late thrombosis.31 Al-
though the extended use of dual anti-platelet therapy
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(DAPT) has helped ensure that stent thrombosis rates
are now less than 1%, the high mortality associated
with these events means that they continue to represent
a signiﬁcant clinical challenge.4 Consequently, much
research in the last decade has focused on the devel-
opment of stents that will inhibit restenosis without
negatively impacting re-endothelialisation.
The drug release proﬁle from ﬁrst generation DES
was controlled through the use of permanent polymer
coatings. The observation that these devices may be
associated with higher rates of thrombosis compared
to BMS,30 served as a stimulus for the development of
biodegradable polymer stent coatings. This alternative
approach provides controlled drug delivery to the
arterial tissue, before the polymer degrades to leave a
BMS in the longer term. Nonetheless, recent clinical
trials (COMPARE II and NEXT trials) found similar
clinical outcomes for biodegradable coatings compared
to durable polymer coated stents DES.23,33
A number of stent surface modiﬁcation strategies
have been investigated in order to provide coatings
that accelerate re-endothelialisation of the lumen. Such
approaches include modiﬁcation of the polymer
chemistry to mimic extra cellular matrix structures and
attachment of molecules to promote cell adhesion.34
The attachment of bioactive molecules appears to be
particularly promising. The Combo stentTM has anti-
CD34 antibodies immobilised on its adluminal surface
to capture circulating endothelial cells, and a sirolimus
releasing coating on the abluminal side to inhibit
smooth muscle cell proliferation. Results from the
REMEDEE clinical trial indicated a regression of ISR
and the absence of thrombosis at 2 year follow up.19
Furthermore, analysis of a small cohort at 60-days
post stenting using optical coherence tomography,
indicated that endothelial coverage was greater and
neointima reduced in the group receiving the Combo
stentTM when compared to an everolimus-eluting
DES.16 However, the Combo stentTM has been unable
to improve outcomes in some groups, with signiﬁcantly
worse outcomes in diabetic patients receiving insulin
compared to non-insulin treated and non-diabetic
individuals.18
Recent work has developed stent coatings with
controlled and well-deﬁned surface micro-topogra-
phies through the use of electrospray (ES) deposition
techniques. By tuning the fabrication parameters, the
resulting micro-topography of the polymer surface
could be optimised.10 Ultrasonic atomisation is a very
widely used method for applying stent coatings, with
many manufacturers of clinically used DES making
use of this technology.8 However, in-depth analysis of
the topographical features of clinically used DES
coatings produced in this way, has gone largely unre-
ported in the literature. As the ultrasonic atomisation
process can be prohibitively expensive for researchers
carrying out pre-clinical development work, many such
studies have instead used a dip coating technique,
which, although convenient, has many drawbacks such
as non-uniform coating, pooling of solution, bridging
of stent struts and lack of control over coating thick-
ness and surface topography.1
In this study, we developed a DES coating with a
bioactive polymer that has been demonstrated to
promote proliferation of human aortic endothelial cells
and inhibit smooth muscle cell proliferation in vitro,24
and which has successfully completed a ﬁrst-in-human
trial,21 in which the stents were coated in polymer
alone (in the absence of any drug). In the present
study, we used a bespoke ES set-up to produce a series
of accelerateTM AT-sirolimus coatings, with optimisa-
tion of the ﬂow, electric ﬁeld and distance across the
electric ﬁeld, providing control of coating thickness,
drug load and roughness of the coating surface. We
characterised sirolimus release from the polymer
coatings by means of an in-vitro dissolution assay and
used atomic force microscopy (AFM) to determine
changes in coating thickness as well as surface rough-
ness following drug release. Finally, we characterised
endothelial cell growth on surfaces that were coated
with polymer alone, in the absence of drug loading.
MATERIALS AND METHODS
Coating Solution Preparation and Substrate Coating
Stent coatings were prepared using a polymer
developed by Biomer Technology Ltd (Runcorn, UK):
accelerateTM AT. The polymer is durable and bio-
compatible, with the composition and distribution of
the functional groups present on the surface designed
to mimic those of the extracellular matrix motif
arginylglycylaspartic acid (RGD) via a combination of
amine, carboxylic acid and hydroxyl groups in the
correct density and proportion. The polymer and sir-
olimus (Cfm Oskar Tropitzsch, Marktredwitz, Ger-
many) were dissolved in equal amounts in
dimethylformamide (DMF) to a ﬁnal concentration of
2% w/v and stored at 4 C until used. A polymer only
solution (2% w/v) was also prepared in DMF and
stored at 4C.
Stainless steel 316L circular coupons (13 mm
diameter, Goodfellow, Huntingdon, UK) and Multi-
linkTM coronary stents (8 mm 9 3 mm, cobalt chro-
mium alloy, Abbott Vascular, CA, USA) were coated
using the 2% polymer/drug solution described above.
The polymer was deposited by means of electrospray-
ing (see Fig. 1), with the potential difference (20 kV)
provided by two high voltage power supplies (Bran-
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denburg, Alpha III, Dudley, UK). Polymer/drug
solution was delivered by an infusion pump (Harvard
Apparatus, PHD 2000, Kent, UK) at a ﬁxed rate of
2 mL/h. Each coupon was electrosprayed for 5, 10, 20
or 30 min. The data collected from this initial investi-
gation were then used to select stent coating times that
would achieve a drug load and coating thickness
comparable to that found on DES used in current
clinical practice.15 Stents were therefore coated for
periods of 10, 20 or 30 min. These coated stents were
crimped onto a 15 mm-long balloon catheter (Conic
Vascular, Santiago de Compostela, Spain) using a
hand crimping tool. Additional circular coupons were
either electrosprayed or dip-coated with the 2% poly-
mer solution alone for use in endothelial cell viability
assays.
Sirolimus Loading and In Vitro Release
Stainless steel 316L circular coupons (n = 3) and
stents (n = 3), coated as described above, were
assessed for in vitro release of sirolimus, according to
our previously detailed methodology.22 Brieﬂy, stents
were expanded to 3 mm diameter and fully immersed
in release medium (phosphate buffered saline (0.01 M):
ethanol (90:10), 1.5 mL). All incubations were carried
out in sealed glass bijous under gyroscopic agitation at
a rate of 20 rpm at 37 C. The coated substrates were
transferred to fresh medium at regular intervals, con-
cluding at 28-days, at which point the coated sub-
strates were immersed in methanol to strip residual
drug. Samples were analysed by ultraviolet spec-
troscopy (Shimadzu Corporation, Japan) and absor-
bance at 278 nm recorded.
Coating Characterisation
The surface roughness and thickness of coatings on
stainless steel 316L circular coupons were quantiﬁed by
Atomic Force Microscopy (AFM) (Oxford Instru-
ments Asylum Research, MFP–3D-BIO, Santa Bar-
bara, CA, USA). Surfaces were scanned in contact
mode using ARiDrive–N01L tips. Representative
scans were collected from three randomly-selected
regions of interest from each coupon (n = 3) having a
scan area of 50 lm 9 50 lm at 0.5 Hz. Images were
ﬂattened in both X and Y axis to reduce alignment
artefacts and their roughness expressed as the root
mean square deviation from the mean line (RRMS). The
thickness of coatings on coupons was established by
physically removing the polymer at three randomly
selected locations on each coupon (n = 3) and scan-
ning at the interface between the polymer and metal
surface. We approximated the thickness of the coating
on the stent surfaces we produced. This was achieved
by calculating the surface area of the stent (0.36 cm2)
using the stent free area (87%) provided by the man-
ufacturer and stent strut dimensions measured from
scanning electron microscope images (see supplemen-
tary information). We used the sirolimus deposition
rate measured from the coupons and stents from our
experiments to calculate a ratio of drug deposition, per
unit area (cm2). Scanning electron micrographs of
stents were obtained using a table-top scanning elec-
tron microscope at an accelerating voltage of 15 kV
(SEM, Hitachi TM1000, Krefeld, Germany).
Cell Culture and Viability Assay
Endothelial cells were isolated from porcine pul-
monary arteries, under local ethical approval, by gentle
scraping of the lumen wall as described elsewhere.12 All
reagents were purchased from Thermo Fisher Scien-
tiﬁc, Paisley, UK. Cells were maintained in Medium
200 enriched with 2% low serum growth supplement
and 1% penicillin/streptomycin and incubated at
37 C. Cells were passaged when sub-conﬂuent using
TrypLE. Cells were used in experiments at passage 3–5
and were seeded at a density of 2 9 104 cells/well onto
polymer coated coupons, uncoated coupons and con-
trol wells in 24-well tissue culture plates in triplicate
(n = 6). At 24-h intervals, culture medium was re-
placed with a 10% solution of alamarBlueTM and
incubated for 1 h. The alamarBlueTM assay is able to
detect redox activity in cells, which is directly related to
cell viability.27 Aliquots (200 lL) of the alamarBlueTM
FIGURE 1. Schematic of electrospray apparatus. The setup
includes high-voltage power supplies (V) connected to both
collector (stent (shown) or coupon) and polymer solution (P).
Polymer is driven to the needle at a rate of 2 mL/h by an
infusion pump. The needle was set at 10 cm from the collector
with the polymer being delivered to the collector across a
potential difference of 20 kV. The collector is driven by a servo
motor which rotates at a rate of 300 RPM. The motor remained
stationary for coating of steel coupons.
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solution were then removed to a 96-well tissue culture
plate and replaced with cell culture medium. Absor-
bance of the aliquots removed at each time point were
then measured at 540 and 620 nm using a UV spec-
trophotometer (Multiskan GO, Thermo Fisher Scien-
tiﬁc, Paisley, UK). The absorbance readings were
processed according to the calculations detailed in the
manufacturer’s instructions, and expressed in terms of
the percentage reduction in alamarBlueTM.
Statistical Analysis
The data presented throughout this work are ex-
pressed as mean values ± standard deviation. Drug
loading and coating thickness data were processed via
linear regression and Pearson’s correlation coefﬁcient in
Excel (Microsoft, CA, USA). All further data analysis
was conducted using Minitab software (Minitab Inc.,
PA, USA) and data were initially tested for normality
using the Ryan–Joiner test. Comparison of coating
thickness and roughness pre and post-elution was anal-
ysed by Students’ paired t test. Comparison of coating
thickness, surface roughness and drug loads between
coating times were analysed using one-way analysis of
variance. Statistical signiﬁcance of cell viability data was
determined following repeated measures two-way anal-
ysis of variance, with post-hoc testing according to Tu-
key’s procedure at a 95% conﬁdence level (p < 0.05).
RESULTS
Polymer-Drug Deposition on Coupons
We measured the thickness of the coating using
AFM (Fig. 2a), and found a linear relationship
between length of coating time and coating thickness
(R2 = 0.97). The corresponding polymer-drug deposi-
tion rate was 102 nm/min for up to 30 min (Fig. 2b).
Stripping of sirolimus from the coatings indicated
that the mass of sirolimus loaded on to the surface was
also time dependent. Increasing coating time resulted
in a near linear increase of sirolimus load at a rate of
approximately 3.4 lg /min (R2 = 0.99) (Fig. 2b). Sir-
olimus was loaded onto the surface of the coupons as
follows: 5-min coating (14.5 ± 3.25 lg), 10-min coat-
ing (33.9 ± 4.61 lg), 20-min coating (72.9 ± 8.34 lg)
and 30-min coating (100 ± 17.4 lg).
Polymer-Drug Deposition on Stents
We estimated that drug was loaded on to stents as
follows: 10-min coating, 17.8 ± 4.09 lg, 20-min coat-
ing, 45.9 ± 2.85 lg and 30-min coating
85.5 ± 9.76 lg. Mean drug load values where plotted
against time and this indicated that there was a strong
positive correlation between coating time and mass of
sirolimus deposited (R2=0.93), with sirolimus being
deposited on to the surface at a rate of approximately
2.62 lg/min (Fig. 3a). Thickness of the coating on
stents was estimated using the deposition rate/cm2 and
indicated that the coating thickness increased at a rate
of approximately 286 nm/min. This calculation
approximated the thickness of the coatings on the
stents to be 2.86, 5.7 and 8.6 lm on the 10- , 20- and
30-min coated stents, respectively.
The release of sirolimus in vitro over a four-week
period, indicated that the total mass eluted by 10-min
coated stents (15.9 ± 4.26 lg) was signiﬁcantly less
than the 20-min coating (37.6 ± 3.67 lg), which in
turn was signiﬁcantly less than the 30-min coating
FIGURE 2. Atomic force microscope representations of drug-eluting polymer coatings on stainless steel coupons and
polymer/drug deposition rates. Coating thickness was measured in three separate regions of interest in each of the coatings
produced (n 5 3). A representative atomic force micrograph of a 30-min polymer coating thickness is shown in (a). The
relationship between both coating thickness (R2 5 0.97) and drug load (R2 5 0.99) with coating time were approximately linear (b)
(n 5 3).
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(81.1 ± 10.3 lg) (all p< 0.05) (n = 3) (Fig. 3b). The
release proﬁles varied for each of the coatings pro-
duced, although all of the coatings had released the
majority of the drug after one day. The 10- and 20-min
coatings released approximately half of the drug within
1-h , with a slower release for the 30-min stent coating,
which did not reach 50% release until 6 h. Complete
release was achieved by the end of the ﬁrst day for the
20-min coating and by day 14 for the 10-min coating.
Again, the 30-min coating release was slower, with
100% release not being recorded until day 21 of the
experiment (Fig. 3c).
Coating Characterisation and In Vitro Stability
The thickness of the coating on the coupons was
unaﬀected by elution/removal of sirolimus, with no
signiﬁcant diﬀerence in thickness between pre-drug
elution and post-drug elution coatings (p > 0.05)
(Fig. 4a). However, the surface roughness was affected
by the coating time, as we detected a signiﬁcant in-
crease in roughness values for the 20-min coating
(154 ± 10.2 nm) when compared to the 5-min coating
(122 ± 7.88 nm) (p < 0.05) (Fig. 4b). Nonetheless,
coatings remained stable following drug elution as no
differences were detected within any of the samples
following the removal of sirolimus, further demon-
strating the in vitro stability of the coating (Fig. 4b).
To monitor uniformity of the polymer coating on
stents, images were acquired before in vitro dissolution
testing using SEM. The 10-min coatings were hetero-
geneous, with the metal stent surface clearly visible
through the coating (Fig. 5a). However, the coating
appeared more uniform when a 20 (Fig. 5b) or 30-min
coating (Fig. 5c) was applied, with the stent surface
completely covered in a homogenous coating. The
FIGURE 3. Coating deposition and sirolimus release from stents. Stents were coated using a 2% polymer: sirolimus solution for
10, 20 or 30 min (n 5 3). Sirolimus was removed from coated stents and quantified using ultraviolet spectroscopy. Regression
analysis indicated that sirolimus was deposited on to the stent surface at a rate of approximately 2.62 lg/min (a). In-vitro release of
sirolimus over a 28-day period indicated a significant increase in cumulative mass released with increasing coating time (*p < 0.05
30-min vs. 20-min coat and **p < 0.05 20-min coat vs. 10-min coat). Data were analysed by one-way ANOVA (b). Percentage mass
released is shown in (c).
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coating also appeared to become thicker with time, as
the edges appeared rounded and less sharp in the 30-
min coating, compared with the 20-min coating. Fol-
lowing sirolimus removal, the 10-min coated stents
appeared to have shed the majority of their coating,
with the large patches that were visible prior to sir-
olimus removal no longer evident (Fig. 5d). Some
cracking appeared around the edges of the struts of the
20 and 30-min coated struts exposing the metallic
surface below (Figs. 5e and 5f).
Endothelial Cell Viability Assay
The viability of primary porcine endothelial cells on
coated and uncoated steel coupon surfaces was moni-
tored at 24-h intervals for a 72-h period. We ﬁrst
measured the surface roughness of the substrates,
which indicated that bare metal (11.1 ± 2.52 nm) and
dip-coated (11.4 ± 2.74 nm) polymer surfaces were
signiﬁcantly smoother than the ES coatings
(104 ± 1.78 nm) (p < 0.001) (Fig. 6a). Cell viability
on the ES coated surfaces was signiﬁcantly greater
than the bare metal following 24 h in culture (Fig. 6b).
Cell activity was also signiﬁcantly greater on surfaces
with a dip-coated polymer coating at each of the time
points measured when compared to the bare metal
surfaces (Fig. 6b). There were no signiﬁcant differences
between either polymer-coated surface over the entire
72-h period.
DISCUSSION
Although DES have revolutionised the treatment of
CAD, the long-term eﬃcacy of current coronary stent
devices has not improved upon outcomes associated
with coronary artery bypass grafting procedures.6
Furthermore, performance of DES remains limited
among some patient groups and in the treatment of
complex lesions,25 whilst prolonged dual anti-platelet
FIGURE 4. Thickness and roughness of electrosprayed drug-eluting coatings on steel coupons. Surface thickness was measured
before and after removal of sirolimus and was shown to be unaffected by this process (a). Roughness of the surface was
significantly increased on 20-min coated coupons when compared to 5-min coating (*p < 0.05) (b). Surface roughness was similar
following 28-day removal of sirolimus for all coatings (b). Data were analysed by students paired t-test and one-way ANOVA.
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therapy is still required in order to reduce the risk of
stent thrombosis in many cases.4 Therefore, there are
opportunities to improve on various aspects of stent
design to improve device efﬁcacy. In this work we
investigated the application of a bioactive polymer
coating and were able to control coating thickness,
drug loading and surface roughness through optimi-
sation of the ES process.
Using the ES process we were able to precisely
control the mass of drug that was deposited on to the
surface of the ﬂat coupons and, to a lesser extent, the
more complex geometry of actual stents. Importantly,
the drug loads on the stent coatings we produced are in
line with second generation DES with durable poly-
mers coatings of the same length (8 mm), such as the
PROMUS (38 lg), Endeavour (84 lg) and Resolute
(59 lg).28 The mass of drug loaded on to stents is an
FIGURE 5. Scanning electron micrographs of electrospray coated drug-eluting stents. Stents were coated with a 2% polymer:
sirolimus solution for 10, 20 or 30 min. Stents were imaged prior to any further manipulation. The 10-min coating appears
heterogeneous with the stent surface still visible (a). Following 20 (c) and 30-min (e) of coating the surface appears uniform and
free from imperfections. The stents were then crimped onto a balloon catheter, expanded and immersed in drug release medium for
28 days and then imaged again. The majority of the coating on the 10-min stent appears to have been removed during drug elution
(b). Some minor cracking appeared within both the 20 (d) and 30-min (f) coatings.
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important determinant of DES efﬁcacy, where a bal-
ance has to be met between achieving a therapeutic
drug concentration within the arterial wall whilst
simultaneously avoiding toxicity to both the smooth
muscle cells and the endothelial cells.3 Findings from
clinical trials have shown a dose-dependent effect of
sirolimus, with increased sirolimus concentration sig-
niﬁcantly inhibiting lumen narrowing and incidence of
restenosis at 6-month follow-up.11 Our more recent
work using accelerate AT coated stents in a porcine
coronary artery model also highlighted the importance
of sirolimus concentration on DES efﬁcacy, with a
signiﬁcant reduction in restenosis achieved with a
higher dose of sirolimus after 28-days when compared
with a lower dose.22
Drug release kinetics are also critical in achieving
the balance between toxicity and therapeutic dose.3
The ideal release rate for a DES is still the subject of
much debate, both slow sustained release and near
zero-order kinetics having been proposed as a means of
achieving optimal target receptor saturation.3,29 The
coatings produced here displayed an initial burst re-
lease of the majority of the drug, with greater than
90% of drug released after one-day. Our recent mod-
elling work using the accelerateTM AT polymer sug-
gests that the mechanism behind this burst release
proﬁle is diffusive transport.22 Despite having a thicker
coating and higher drug load, the 20-min stent had
released 100% of drug by day one, whilst the 10 min-
coated stent did not reach 100% release until day 14. A
potential explanation for this is the difference in the
FIGURE 6. Viability of primary endothelial cells on drug-free electrospray coated and uncoated surfaces. Surface roughness on
bare metal, dip-coated and electrosprayed polymer surfaces was measured by atomic force microscopy and indicated a
significantly greater roughness value for electrosprayed surfaces, compared to bare metal and dip coated surfaces (*p < 0.05) (a).
Cells were seeded at a density of 2 3 104 cells/well onto polymer coated coupons, uncoated coupons and control wells in 24-well
tissue culture plates in triplicate (n 5 6). Cell viability was measured every 24 h for up to 72 h using an alamarBlueTM reduction
assay (b). There was a significantly greater cellular viability on dip coated surfaces compared to bare metal at each time point,
(ap < 0.05). At 24 h cell viability was greater on the electrosprayed surface when compared to the bare metal surface, (*p < 0.05).
Cell viability was similar between the two polymer coated surfaces throughout. Data were analysed by 2-way repeated measures
ANOVA with Tukey post-hoc comparisons.
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surface roughness, with previous work indicating that
rougher surfaces released drug faster when compared
to planar surfaces, which is likely due to an increase in
surface area.20 The 30-min coatings examined dis-
played a bi-phasic release proﬁle similar to the 10-min
coating, with an initial burst followed by a second,
relatively slow phase. Whether this difference was di-
rectly related to the drug load or coating thickness, or
both, remains to be seen. However, these ﬁndings
warrant further investigation of the ES process and its
utility in producing coatings with variation in drug
load, coating thickness and surface roughness in order
to identify the key parameters for further optimisation
of the drug release proﬁle. Further modiﬁcation of the
release kinetics could be achieved by addition of a
drug-free polymer only top coat in order to slow re-
lease. Such a strategy was employed during the devel-
opment of the ﬁrst generation CYPHER DES, with a
fast release device, which had similar release kinetics to
the coatings we have produced, modiﬁed by the addi-
tion of a top coat which drastically slowed release. 32
Nonetheless, fast release polymer-free DES have
demonstrated comparable clinical outcomes to exist-
ing, slow release polymer coated DES (BioFreedom
trial) at 5-year follow up.7 Furthermore, these devices
have been demonstrated to be safe and efﬁcacious in
high bleeding risk patients. 9 The release of the
majority of drug in the initial burst phase of the DES
shown here ﬁts with the rationale behind such polymer
free stents, although after the drug is released a
bioactive polymer would remain rather than a bare
metal surface.
It has been suggested that the thickness of the
polymer coating impacts on the safety of the stent,
with recent computational studies indicating that
thicker coatings pose a greater risk of deformity.13
Such deformities in durable polymer coatings have the
potential to induce thrombosis and increase ISR when
implanted in vivo.2 The thickest coating that we
examined was in the region of 8 lm (30-min deposition
time), which is below the range tested in the afore-
mentioned study, but consistent with the typical coat-
ing thickness reported for currently used DES.13 While
our coatings did show some evidence of minor defor-
mities, we made this observation after they had been in
release medium for 28-days following expansion under
pressure. In the case of the 20 and 30-min coatings,
some cracking appeared around the edge of the stent
struts leading to some exposure of the underlying metal
but there was no evidence of delamination. The mag-
nitude of these areas of exposure is relatively small in
comparison to the ‘craters’ that have been reportedly
found in the coating of DES intended for clinical use.2
Other imperfections that have previously been
reported with stent coatings, such as polymer webbing
between struts, buckling and coating fragmentation,
for example, were not evident in any of the coatings
produced in the present study.2
Recent work by Guo et al.,10 demonstrated that
polymer deposition on to coronary stents by means of
ES can be ﬁne-tuned to allow control over the polymer
surface topography at a micro scale, which may allow
for recapitulation of the topographical features of tis-
sue and therefore promote integration of the device
in vivo.10 We applied this method to produce coatings
using a polymer that has been designed such that it
mimics RGD. The RGD peptide sequence is found on
proteins present in the basement membrane of native
arteries, and is required for cell adhesion, which is a
crucial step in cellular interaction with the substrate.34
Earlier work demonstrated that growth of primary
human aortic endothelial cells was promoted on this
material and proliferation of smooth muscle cells was
not stimulated.24 The viability of cells attached to the
surface of the accelerateTM AT coatings produced by
electrospraying or dip coating was signiﬁcantly greater
when compared to stainless steel surfaces. This result
notwithstanding, it remains unclear to what extent the
modiﬁed surface impacts on the normal functioning of
the endothelial cell layer. The endothelium plays an
important role in the regulation of vascular function,
not least the regulation of vascular tone and perme-
ability and the prevention of thrombosis.26 To fully
evaluate the impact of the accelerate polymer on the
function of the endothelium will require future evalu-
ation in vivo and ex vivo.
In conclusion, we were able to demonstrate the
utility of the ES process for the production of drug-
eluting polymer coatings for application on to coro-
nary stents. Optimisation of the process allowed for a
degree of control over a number of surface and coating
characteristics, including drug load, coating thickness
and surface roughness. The stents we produced are
comparable to DES currently used in clinical practice,
with similar drug loads and release kinetics, as well as
coating thickness. Furthermore, we have shown that
coatings produced using this ES process can accelerate
the attachment of primary porcine endothelial cells to
the surface. The novel dual-acting stent we produced
has signiﬁcant therapeutic potential to inhibit
restenosis through rapid release of sirolimus in the
short term, and promote vessel healing through the
restoration of a conﬂuent endothelial layer in the
longer term by virtue of the bioactive properties of the
polymer coating. That the roughness of the polymer
coating remained largely unchanged after drug elution,
providing a relatively smooth and stable substrate on
which ECs have been shown to grow and adhere, and
which is able to resist thrombosis in the short term and
ISR in the longer term, is a further beneﬁt with
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important implications for the success of this
approach. Clearly further work is needed, but the
ﬁndings of this in vitro study may help to make the case
for further pre-clinical and clinical trials and also open
up opportunities to investigate the impact of drug
loads and release kinetics on DES performance using
the controlled ES process.
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